A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Latest Information Update: 09 May 2024
At a glance
- Drugs Ibrutinib (Primary) ; Palbociclib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 03 May 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 03 May 2024 Planned primary completion date changed from 1 Jun 2024 to 30 Jun 2025.
- 31 May 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.